Parasitological association between human leishmaniosis mucosa and paracoccidioidomycosis. Case report

Carlos Augusto de Jesus Oliveira Gonçalves a,⁎, José Thiers Carneiro Jr a, Eduardo Luis de Souza Cruz b, Francisco de Sousa Neves Filho b, Roberto Carlos Rivadeneira Cárdenas b, Douglas Magno Guimarães c

a Opel Loyola Hospital, Governador Magalhães Barata Avenue, 992, Belém, PA, 66063-240, Brazil
b Federal University of Pará, Augusto Correa Street, 01, Belém, PA, 66075-110, Brazil
c Oral Pathology at Centro Universitário do Pará, 9 de Janeiro Avenue, 927, Belém, PA, 66060-370, Brazil

A R T I C L E   I N F O

Article history:
Received 31 July 2020
Received in revised form 19 September 2020
Accepted 19 September 2020
Available online 23 September 2020

Keywords:
Leishmaniosis
Paracoccidioidomycosis
Oral manifestations
Parasitological association

A B S T R A C T

INTRODUCTION: Leishmaniosis Mucosa (LM) is a tropical disease that affects the upper respiratory tract and/or oral mucosa. Its etiological agent is Leishmania spp. Paracoccidioidomycosis disease caused by the fungus Paracoccidioides brasiliensis. The aim is to report a case of Leishmaniosis Mucosa in association with Paracoccidioidomycosis.

PRESENTATION OF CASE: A male patient, 24 years old: Introrally, presence of a non-bleeding erythro-leuco-plastic lesion that affected the soft palate and oropharynx; 3 years of evolution. On the face Computerized Tomography (CT) examination, it was possible to observe muco-periosteal thickening in the soft palate region; immunohistochemical markings for Paracoccidiodes brasiliensis. He was diagnosed with Leishmaniosis by Montenegro intradermoreaction (MIDR).

DISCUSSION: The predisposition to Paracoccidioidomycosis after Leishmaniosis infection is justified by factors already elucidated – hygiene, nutrition habits and immunodeficiency, but the reason for the non-progression of the fungus after years of evolution could be related to its inhibition due to the presence of the protozoan in the same wound.

CONCLUSION: This phenomenon may be explained by future studies that need to be performed to answer such questions.

© 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Leishmaniosis is a tropical disease clinically classified according to the involvement of anatomical regions, such as: visceral (VL), cutaneous (CL) and Mucocutaneous (MCL); It may affect oral mucosa areas alone. Leishmaniosis Mucosa (LM) is a chronic infection that affects the upper respiratory tract and/or oral mucosa. The etiological agents Leishmania braziliensis, followed by L. panamensis and L. amazonenses are the main causers of LM [1–3].

It is a geographically dispersed disease. There are transmission relates on five continents and endemic rates in 98 countries. The incidence of leishmaniosis is very high in India, Bangladesh, Nepal, Brazil and Sudan. According to the World Health Organization (WHO), the disease has spread worldwide and two million new cases are estimated per year (1.5 million cases of CL and 500 000 VL cases, with approximately 12 million infected individuals). In the Americas, there are case records in all countries except Chile and Uruguay [4–6].

The MCL form is the most severe and it appears a few years after the integumentary manifestation. It affects the upper part of the aerodigestive tract, with mainly lesions in the oral nasal mucosa and occasionally in the larynx and pharynx. The exclusive involvement of oral mucosa is quite rare [6].

Clinical presentation is largely determined by the host’s immune response. In general, it presents as erythema and ulceration or as exophytic plaque, papules and/or nodules, usually affecting hard palate, soft palate and tongue. However, they can affect any site such as the lip, uvula, gingiva, amygdala and retromolar region, associated with pain, edema, foul smell, bleeding and sialorrhea [3].

Other infectious/non-infectious diseases may show similar lesions, among them: paracoccidioidomycosis; histoplasmosis; tuberculosis; leprosy; lethal midline granuloma; pemphigus vulgaris; pemphigoid; plasmacytic gingivitis; anemias; leukemia and verrucous carcinoma [7].

The diagnosis of leishmaniosis is a real challenge for all professional team. At first, the clinical manifestations of the disease

https://doi.org/10.1016/j.ijscr.2020.09.128
2210-2612/© 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
present a wide differential diagnosis and the findings may be associated with other diseases, such as Paracoccidioidomycosis, which is an infectious disease caused by the fungus Paracoccidioides brasiliensis. It causes tegumentary lesions as one of its main clinical manifestations. The patients often present ulcerations in bucal, nasal and oropharyngeal mucosa; besides pulmonary findings [8,9].

The aim of this work is to report a case of Leishmaniasis Mucosa in association with Paracoccidioidomycosis and to discuss the existence of an infectious relationship between parasites for exclusive findings on oral mucosa in humans. This work has been reported in accordance to the Surgical Case Report (SCARE) guidelines [10].

2. Case report

A male patient, meloderma, a construction worker, 24 years old. He presented himself at the Oral and Maxillofacial Surgery Service complaining about mouth injury, causing dysphagia due to burning and pain. In the anamnesis, there was a clinical course with an evolution of approximately 3 years, with hospitalizations occurring under suspicion of severe tonsillitis with no positive response for treatment.

Physical examination revealed an individual with a symmetrical, normocorate and a febrile face; Absence of regional infected and painfully lymph nodes. Intraorally, total denture with satisfactory hygiene; presence of a non-blooding erythro-leucoplastic lesion with irregular surface and diffuse contours that affected the soft palate and oropharynx (Fig. 1).

On the Computerized Tomography (CT) of the face examination, it was possible to observe muco-periosteal thickening of apparently inflammatory origin in the soft palate region with absence of bone involvement in the involved region, with free airways (Fig. 2).

Negative results for HIV, Syphilis (VDRL / FTABS) and Tuberculosis (Escarro T.); without radiographic signs of paracoccidioidomycosis (Paracoccidioides brasiliensis) in the thorax. Material was collected for incisional biopsy demonstrating non-specific chronic inflammatory tissue sections with immunohistochemical markings for Paracoccidioides brasiliensis (Fig. 3).

The patient was asked to go to the Center for Tropical Diseases of the Evandro Chagas Institute/PA where he was diagnosed with Leishmaniasis by Montenegro intradermoreaction (MIDR). The treatment was started with Fluconazole 400 mg twice a day for one month in combination with Nystatin-based mouth wash three times a day. In 10 days’, return there was a slight improvement in the condition.

3. Discussion

Leishmaniasis is an infectious disease obligatory caused by protozoan parasites of the genus Leishmania. American tegumentary leishmaniasis can reach individuals of any age, being more frequent from 20 to 40 years old. The incidence of leishmaniasis as an opportunistic disease has increased in recent years due to the increasing number of patients with immunological depression secondary to chronic diseases, neoplasms, organ transplants, immunosuppressive treatments and human immunodeficiency virus (HIV) becoming a public health problem [6,7,11].

In Brazil, the highest incidence of Leishmaniasis is in the Northern Region, which comprises the States of Acre, Amapá, Amazonas,
Pará, Rondônia, Roraima and Tocantins. Actually, it is one of the macro regions considered endemic by the disease [12].

The presented article refers to a case of Leishmaniasis with exclusive involvement of oral mucosa and oropharynx, without affecting nasal mucosa area and previous skin lesions as in most cases of muco-cutaneous Leishmaniasis, which made it difficult to diagnose the disease. The time of evolution is the factor that determines the dissemination of the parasite and is one of the main responsible for the severity of the mucosal lesions and their consequences. Therefore, it is essential to diagnose the disease early [7].

The diagnosis is made by clinical findings, epidemiology and laboratory tests. The test is positive in 75% of the lesions whose evolution varies from two to six months and in 20% after this time. Hamster culture and inoculation have sensitivity of 30 and 50%, respectively. Montenegro intraderma reaction (MIDR) is positive in 82.4–100% at the time of diagnosis. It may be negative in the disease with up to four months of evolution, in diffuse cutaneous Leishmaniasis (DCL) and in immunocompromised patients [11,12].

Generally, cuts for the evaluation of Leishmania amastigotes are difficult to visualize and differentiate from amastigotes from other microorganisms. Considering the rarity of Leishmaniasis in the upper aerodigestive tract region, the diagnosis of (LM) can be challenging, because even with clinically active lesions, amastigotes are generally scarce and other auxiliary methods for confirming the diagnosis are used, as in the case in question that the final diagnosis was closed by (IDRM) which is effective and low cost [13].

The characteristics of the case reported in association with the longitude of progression suggested some diagnostic hypotheses such as squamous cell carcinoma, tuberculosis and paracoccidoidal mycosis. The presence of Paracoccidioides brasiliensis in the histological sections initially showed the parasite as a possibly causing agent of the clinical condition which could be related to the professional activity of the individual, nutritional deficiencies and inadequate hygiene. However, the lack of other clinical signs justifying Paracoccidioidomycosis, such as lung lesions and the negative response to initial therapy encouraged the search for new hypotheses and confirmation of the diagnosis of Leishmaniasis after a positive MIDR test [14].

It is believed that the cellular immunity of the host is very important in the therapeutic response of Leishmaniasis in view of being an intracellular parasite. Mucosal Leishmaniasis is a debilitating disease that can cause malnutrition and immunodepression, leading to secondary infections that may become more serious than the underlying disease itself, which may explain paracoccidioidomycosis as a secondary parasitic form of the disease [11,12].

Paracoccidioidomycosis is an endemic systemic mycosis in Latin American countries. The etiological agent Paracoccidioides brasiliensis is a thermophile fungus that grows as a yeast in the host at 37°C and as a mycelium at 25°C. Primary infection usually occurs in the lungs by inhalation, and can spread to the body through the lymphatic or hematogenic system. Mucosal and skin lesions, as well as involvement of lymph nodes and adrenal glands can be clinically identified [8,14–16].

Secondary manifestations of this pathology can affect the oral cavity, which leads the patient to seek the dental surgeon. Exceptionally, traumatic inoculation of the fungus by the tegument system is possible. Infection can also be established in the skin and mucosa by inoculation through other pre-existing lesions, which may explain the presence of yeasts in the histological sections and the non-involvement of the lungs in the reported case [14,15].

Authors study the possible association of Leishmaniasis and Paracoccidioidomycosis in serum studies of 836 dogs, of which 449 were positive serum for Leishmaniasis, while 387 were negative serum. The main antigen of Paracoccidioides brasiliensis (gp43) had a higher reactivity in dogs with Leishmaniasis (79.9%) than in negative serum dogs (54%) [15].

The reported case showed coexistence of both parasites in the same infected individual. The predisposition to Paracoccidioidomycosis after Leishmaniasis infection is justified by factors already elucidated, but the reason for the non-progression of the fungus after years of evolution could be related to its inhibition due to the presence of the protozoan in the same wound. This phenomenon may be explained by future studies that need to be performed to answer such questions [15].

The management of leishmaniasis still represents a great challenge, its treatment is equally variable and still controversial, with no universal consensus on the most effective type of medication, period of use, latency periods and control of its sequelae. Local treatment of small lesions may not be necessary, as larger lesions may be treated with surgical excision, curettage, or cryotherapy. A limited number of drugs are available for the treatment of leishmaniasis, and some systematic reviews tried to reach a consensus on an ideal drug treatment for patients using different interventions. In general, no single therapy is 100% effective for leishmaniasis [4,7,17].

The use of some medications has been proposed, such as pentavalent antimony, lipid compounds associated with amphotericin, oral imidazole compounds, and several other local or topical treatments. There is interest in oral anti-manic agents and azole therapy, which comprises fluconazole, ketoconazole and itraconazole which
can be an alternative that fulfills this requirement. Fluconazole has advantages over other azoles, including a longer half-life, increased skin tissue concentrations, and low toxicity [7,18].

We opted for drug treatment since the patient had no bone or airway involvement, no fistula or infectious process that would justify the surgical approach, conservative therapy is always the first choice and has been shown to be effective, as observed in a systematic review with azole therapy [18].

4. Final considerations

The strictly mucosal involvement in leishmaniasis is the most serious complication of L. braziliensis infections and may lead to a disfiguring and potentially fatal condition in a variable proportion of patients. In addition, associations with other infectious diseases, such as Paracoccidioidomycosis may exist with potential parasitological synergism that needs to be better studied.

Declaration of Competing Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Sources of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

Does not refer to our study, exempt ethical statement for this type of paper.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

All authors contributed to each stage of the paper's development. The Ophir Loyola Hospital (Belém, Pará, Brazil) for their valuable contribution in reference monitoring for patients and support to professionals; also, to able to give conditions for this study could be performed. Centro Universitário do Pará – CESUPA (Belém, Pará, Brazil) and Evandro Chagas Institute (Belém, Pará, Brazil) for all collaboration in the diagnosis, treatment and preparation of this manuscript.

Registration of research studies

1 Name of the registry:
2 Unique identifying number or registration ID:
3 Hyperlink to your specific registration (must be publicly accessible and will be checked):

 Guarantor

Carlos Augusto de Jesus Oliveira Gonçalves

Provenance and peer review

Not commissioned, externally peer-reviewed

Acknowledgements

We thank the Ophir Loyola Hospital (Belém, Pará, Brazil) for their valuable contribution in reference monitoring for patients and support to professionals; also, to able to give conditions for this study could be performed. The whole team, our sincere thanks.

We thank the Centro Universitário do Pará – CESUPA (Belém, Pará, Brazil) and Evandro Chagas Institute (Belém, Pará, Brazil) for all collaboration in the diagnosis, treatment and preparation of this manuscript.

References

[1] A. Celentano, E. Ruoppo, G. Mansueto, M.D. Mignogna, Primary oral leishmaniasis mimicking oral cancer: a case report, B J Oral and Maxillofac Surg 53 (4) (2015) 396–398.
[2] A.F. Cruz, R.G. Resende, D.R. Albuquerque, J.C.T. De Lacerda, C.F. Leite, M.C.F. Aguiar, Mucosal leishmaniasis in Brazilian patients: two case reports with similar clinical presentation and different approaches, Oral Surg Oral Med Oral Pathol Oral Radiol 122 (6) (2016) e199–e203.
[3] T.F.A. Almeida, E.M. Da Silveira, C.R.R. Dos Santos, J.E. León, A.T.M. Mesquita, Exclusive primaryy esional oral leishmaniasis with immunohistochemical diagnosis, Head Neck Pathol. 10 (4) (2016) 533–537.
[4] M.D. Mignogna, A. Celentano, S. Leuci, M. Cascone, D. Adamo, E. Ruoppo, G. Fasola, Mucosal leishmaniasis with primary oral involvement: a case series and a review of the literature, Oral Dis. 21 (1) (2015).
[5] S. Garg, R. Tripathi, K. Tripathi, Oral mucosal involvement in visceral leishmaniasis, Asian Pacific J Trop Med 6 (3) (2013) 249–250.
[6] A.C.A. Pellicioli, M.A. Martins, M.S.A. Filho, P.V. Rados, M.D. Martins, Leishmaniasis with oral mucosal involvement, Gerodontology 29 (2) (2012).
[7] M.E.S.M. Santos, E.F.D.C. Nogueira, P.H.D.S. S. B.C.A. Torres, Leishmaniose mucocutânea facial: desafios do diagnóstico ao tratamento, RevCiTraumatol Buco-maxilo-fac 13 (2) (2013) 15–21.
[8] J.S. Rosario, P.F. Toledo, R.A. Nicolau, C.P. Deco, A.C.V. Canettieri, Diagnóstico e tratamento de paracoccidioidomicose: relato de caso clinico, RevUnivap 22 (40) (2017) 641.
[9] A.L. Colombo, L.F.A. Camargo, O.G. Fischman, A. Castelo, Parâmetros clínicos relevantes para o diagnóstico diferencial entre leishmaniose cutâneo-mucosa e paracoccidioidomicose, RevSoc Bras Med Trop 25 (1992) 171–175.
[10] Agha Ra, Borrelli Mr, R. Farwana, K. Koshy, A. Fowler, Orgill Dp, For the SCARE Group, The SCARE 2018 statement: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136.
[11] D. Velozo, A. Cabral, M.C.M. Ribeiro, J.D.O.C.D. Motta, L.M.C. Costa, R.N.R. Sampaio, Leishmaniose mucosa fatal em criança, An Bras Dermatol 81 (3) (2006) 255–259.
[12] S.A. Basano, L.M.A. Camargo, Leishmaniose tegumentar americana: histórico, epidemiologia e perspectivas de controle, RevBrasEpidemiol 7 (2004) 328–337.
[13] Celeste Sánchez-Romero, et al., Immunohistochemical and molecular diagnosis of mucocutaneous and mucosal leishmaniasis, Int. J. Surg. Pathol. 28 (2) (2020) 138–145.
[14] M.R.P. Fortes, H.A. Miot, C.S. Kurokawa, M.E.A. Marques, S.A. Marques, Immunology of paracoccidioidomycosis, An Bras Dermatol 86 (3) (2011) 516–524.
[15] L.H. Silveira, I.H. Domingos, K. Kouchi, E.N. Itano, E.A. Silva, V.O. Landgraf, M.A. Ono, Serological detection of antibodies against Paracoccidioides brasiliensis in dogs with leishmaniasis, Mycopathologia 162 (5) (2006) 325.
[16] R.G. Alexo, M.T.V. Rodrigues, D.O.R. Do Nascimento, D.T. Oliveira, Manifestações bucais da paracoccidioidomicose: a importância para o cirurgião-dentista–relato de caso, ClípeOdont 8 (2) (2016) 45–50.
[17] M.Z. Handler, P.A. Patel, K. Kapila, Y. Al-Qubati, R.A. Schwartz, Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management, J. Am. Acad. Dermatol. 73 (6) (2015) 911–926.
[18] E.L. Galvao, A. Rabello, C.F. Cota, Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis, PLoS One 12 (10) (2017), e0186117.